On the other side, the positive correlation also can be found between SYK expression and the pathogenesis of non-alcoholic steatohepatitis (NASH), and the administration of SYK inhibitor (R406) with PLGA nanoparticles is regarded as a potential therapeutic approach against mouse NASH [40]. Here, SYK is linked to metabolic dysfunction-associated steatohepatitis.